Endocannabinoid System Components as Potential Biomarkers in Psychiatry
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
The high heterogeneity of psychiatric disorders, leads to a lack of diagnostic precision. Therefore, the search of biomarkers is a fundamental aspect in psychiatry to reach a more personalized medicine. The endocannabinoid system (ECS) has gained increasing interest due to its involvement in many different functional processes in the brain, including the regulation of emotions, motivation and cognition. This article reviews the role of the main components of the ECS as biomarkers in certain psychiatric disorders. Studies carried out in rodents evaluating the effects of pharmacological and genetic manipulation of cannabinoid receptors or endocannabinoids (eCBs) degrading enzymes. Likewise, the ECS-related alterations occurring at the molecular level in animal models reproducing some behavioral and/or neuropathological aspects of psychiatric disorders were reviewed. Clinical studies evaluating gene or protein alterations in post-mortem brain tissue or in vivo blood, plasma and cerebrospinal fluid (CSF) samples were analyzed. Furthermore, the results from neuroimaging studies using positron emission tomography (PET) or functional magnetic resonance (fMRI) were included. This review shows the close involvement of cannabinoid receptor 1 (CB1r) in stress regulation and the development of mood disorders (anxiety, depression, bipolar disorder (BD)), in post-traumatic stress disorder (PTSD), as well as in the etiopathogenesis of schizophrenia, attention deficit hyperactivity disorder (ADHD) or eating disorders (i.e. anorexia and bulimia nervosa). On the other hand, recent results regarding the potential therapeutic action of the endocannabinoid tone manipulation by inhibition of eCBs degrading enzymes, as well as by the modulation of cannabinoid receptor 2 (CB2r) activity on anxiolytic, antidepressive or antipsychotic associated effects were included. Further clinical research studies are needed, however, current evidence suggests that the components of the ECS may become promising biomarkers in psychiatry to improve, at least in part, the diagnosis and pharmacological treatment of psychiatric disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“CB2 cannabinoid receptor (CB2r) was initially considered as a peripheral cannabinoid receptor due to its high expression in the rat spleen (34) and leukocyte subpopulation in humans (32), participating in the regulation of the immune system (35).”
BackgroundStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 1×
“The two main eCBs are derivatives of polyunsatured fatty acids, N-arachidonoylethanolamine (anandamide, AEA) (51), and 2-arachidonoylglycerol (2-AG), being the most abundant eCBs in the brain (52).”
BackgroundEstimating the true global burden of mental illness
Vigo, D., Thornicroft, G., & Atun, R. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00505-2 · Cited by 2,494
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 2×
“The eCBs are lipid messengers acting as paracrine, autocrine, and probably endocrine mode, because their lipid nature allows them to diffuse and cross membranes (15, 17, 18, 48, 49).”
BackgroundOwen, M. J., Sawa, A., & Mortensen, P. B. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01121-6 · Cited by 1,870
Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586
Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Brain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373 · cited 1×
“Monoacylglycerol lipase (MAGL) is a serine-hydrolase enzyme mainly found in presynaptic terminals that catalyzes 2-AG into arachidonic acid and glycerol (55, 60).”
BackgroundModulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097
The endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090 · cited 1×
“g 2 The endocannabinoid system (ECS) components (receptors, ligands, synthesizing and degrading enzymes) have gained a special interest because of their critical neuromodulatory involvement in a plethora of functional mechanisms in the central nervous system (CNS), including emotional regulation, motivational behavior…”
BackgroundCollaborators, O. B. O. T. W. W. M. H. S., Fayyad, J., Sampson, N. A., Hwang, I., Adamowski, T., Aguilar-Gaxiola, S., Al-Hamzawi, A., Andrade, L. H. S. G., Borges, G., de Girolamo, G., et al. (2017) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-016-0208-3 · Cited by 824
Cannabinoid CB2 receptors: immunohistochemical localization in rat brain
Gong, J.-P., Onaivi, E. S., Ishiguro, H., Liu, Q.-R., Tagliaferro, P. A., Brusco, A., & Uhl, G. R. (2006) · Brain Research · doi:10.1016/j.brainres.2005.11.035 · Cited by 820
Distribution of cannabinoid receptors in the central and peripheral nervous system
Mackie, K. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_10 · Cited by 744 · cited 10×
“CB1r is widely distributed in brain areas associated with emotional regulation and stress responsiveness such as PFC, Hipp, Amy, and Hyp (19).”
BackgroundInfluentialMultiple Functions of Endocannabinoid Signaling in the Brain
Katona, I., & Freund, T. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062111-150420 · Cited by 630 · cited 3×
“The eCBs are lipid messengers acting as paracrine, autocrine, and probably endocrine mode, because their lipid nature allows them to diffuse and cross membranes (15, 17, 18, 48, 49).”
BackgroundThe endocannabinoid system in guarding against fear, anxiety and stress
Lutz, B., Marsicano, G., Maldonado, R., & Hillard, C. J. (2015) · Nature reviews. Neuroscience · doi:10.1038/nrn4036 · Cited by 506 · cited 1×
“However, our knowledge on the precise molecular mechanisms of the ECS signaling in humans is insufficient (68, 69).”
BackgroundThe Endocannabinoid System and Pain
Guindon, J., & Hohmann, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824660 · Cited by 476
Gao, Y., Vasilyev, D. V., Goncalves, M. B., Howell, F. V., Hobbs, C., Reisenberg, M., Shen, R., Zhang, M.-Y., Strassle, B. W., Lu, P., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5693-09.2010 · Cited by 473
Tanimura, A., Yamazaki, M., Hashimotodani, Y., Uchigashima, M., Kawata, S., Abe, M., Kita, Y., Hashimoto, K., Shimizu, T., Watanabe, M., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.01.021 · Cited by 472 · cited 1×
“The degradation of these precursors by diacylglycerol lipases (DAGL-a and DAGL-b) drives 2-AG synthesis (58, 59).”
BackgroundHeyman, E., Gamelin, F.-X., Goekint, M., Piscitelli, F., Roelands, B., Leclair, E., Di Marzo, V., & Meeusen, R. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.09.017 · Cited by 427
Cabral, G. A., & Griffin-Thomas, L. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409000957 · Cited by 408
Enhancing Cannabinoid Neurotransmission Augments the Extinction of Conditioned Fear
Chhatwal, J. P., Davis, M., Maguschak, K. A., & Ressler, K. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300655 · Cited by 376
Neumeister, A., Normandin, M. D., Pietrzak, R. H., Piomelli, D., Zheng, M. Q., Gujarro-Anton, A., Potenza, M. N., Bailey, C. R., Lin, S. F., Najafzadeh, S., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.61 · Cited by 361
The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety
Haller, J., Bakos, N., Szirmay, M., Ledent, C., & Freund, T. F. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02192.x · Cited by 354
Egertová, M., Cravatt, B. F., & Elphick, M. R. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00145-3 · Cited by 347 · cited 1×
“AEA is inactivated by fatty acid amide hydrolase (FAAH) present in many organs and in the brain at postsynaptic location (55, 56).”
BackgroundZhang, H.-Y., Gao, M., Liu, Q.-R., Bi, G.-H., Li, X., Yang, H.-J., Gardner, E. L., Wu, J., & Xi, Z.-X. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413210111 · Cited by 334 · cited 1×
“Interestingly, in some of these brain regions, CB2r was detected not only in the microglia (45) but also in the neurons (44, 46, 47).”
BackgroundHill, M. N., Miller, G. E., Carrier, E. J., Gorzalka, B. B., & Hillard, C. J. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.03.013 · Cited by 328
Bambico, F. R., Katz, N., Debonnel, G., & Gobbi, G. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1636-07.2007 · Cited by 325
Gunduz-Cinar, O., MacPherson, K. P., Cinar, R., Gamble-George, J., Sugden, K., Williams, B., Godlewski, G., Ramikie, T. S., Gorka, A. X., Alapafuja, S. O., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.72 · Cited by 307
Bahi, A., Al Mansouri, S., Al Memari, E., Al Ameri, M., Nurulain, S. M., & Ojha, S. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.06.003 · Cited by 291
FAAH genetic variation enhances fronto-amygdala function in mouse and human
Dincheva, I., Drysdale, A. T., Hartley, C. A., Johnson, D. C., Jing, D., King, E. C., Ra, S., Gray, J. M., Yang, R., DeGruccio, A. M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7395 · Cited by 289
Haller, J., Varga, B., Ledent, C., Barna, I., & Freund, T. F. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03293.x · Cited by 284
Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses
Busquets-Garcia, A., Puighermanal, E., Pastor, A., de la Torre, R., Maldonado, R., & Ozaita, A. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.022 · Cited by 273
Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects
Onaivi, E. S., Ishiguro, H., Gong, J.-P., Patel, S., Meozzi, P. A., Myers, L., Perchuk, A., Mora, Z., Tagliaferro, P. A., Gardner, E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001640 · Cited by 257
Hill, M. N., Bierer, L. M., Makotkine, I., Golier, J. A., Galea, S., McEwen, B. S., Hillard, C. J., & Yehuda, R. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.08.004 · Cited by 256
Hill, M. N., Carrier, E. J., McLaughlin, R. J., Morrish, A. C., Meier, S. E., Hillard, C. J., & Gorzalka, B. B. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05567.x · Cited by 246
Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety
Gray, J. M., Vecchiarelli, H. A., Morena, M., Lee, T. T. Y., Hermanson, D. J., Kim, A. B., McLaughlin, R. J., Hassan, K. I., Kühne, C., Wotjak, C. T., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2737-14.2015 · Cited by 246
Haller, J., Varga, B., Ledent, C., & Freund, T. F. (2004) · Behavioural Pharmacology · doi:10.1097/01.fbp.0000135704.56422.40 · Cited by 241
Hill, M. N., Kumar, S. A., Filipski, S. B., Iverson, M., Stuhr, K. L., Keith, J. M., Cravatt, B. F., Hillard, C. J., Chattarji, S., & McEwen, B. S. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.90 · Cited by 222
Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors
Urigüen, L., Pérez-Rial, S., Ledent, C., Palomo, T., & Manzanares, J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.01.003 · Cited by 218
Self-citationPrepulse inhibition and genetic mouse models of schizophrenia
Powell, S. B., Zhou, X., & Geyer, M. A. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.04.021 · Cited by 218
Micale, V., Cristino, L., Tamburella, A., Petrosino, S., Leggio, G. M., Drago, F., & Di Marzo, V. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.98 · Cited by 207
Depression‐resistant endophenotype in mice overexpressing cannabinoid CB 2 receptors
García‐Gutiérrez, M., Pérez‐Ortiz, J., Gutiérrez‐Adán, A., & Manzanares, J. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00819.x · Cited by 196
Self-citationCannabinoids modulate hippocampal memory and plasticity
Abush, H., & Akirav, I. (2010) · Hippocampus · doi:10.1002/hipo.20711 · Cited by 186
Sciolino, N. R., Zhou, W., & Hohmann, A. G. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.04.010 · Cited by 179
Kinsey, S. G., O'Neal, S. T., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.12.002 · Cited by 170
Anxiety, stress, and fear response in mice with reduced endocannabinoid levels
Jenniches, I., Ternes, S., Albayram, O., Otte, D. M., Bach, K., Bindila, L., Michel, K., Lutz, B., Bilkei-Gorzo, A., & Zimmer, A. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.033 · Cited by 169
Cannabinoid facilitation of fear extinction memory recall in humans
Rabinak, C. A., Angstadt, M., Sripada, C. S., Abelson, J. L., Liberzon, I., Milad, M. R., & Phan, K. L. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.063 · Cited by 163
Depression-like phenotype following chronic CB1 receptor antagonism
Beyer, C. E., Dwyer, J. M., Piesla, M. J., Platt, B. J., Shen, R., Rahman, Z., Chan, K., Manners, M. T., Samad, T. A., Kennedy, J. D., et al. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.03.020 · Cited by 160
Haller, J., Barna, I., Barsvari, B., Gyimesi Pelczer, K., Yasar, S., Panlilio, L. V., & Goldberg, S. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1494-7 · Cited by 159
Bluett, R. J., Gamble-George, J. C., Hermanson, D. J., Hartley, N. D., Marnett, L. J., & Patel, S. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.53 · Cited by 157
Shonesy, B. C., Bluett, R. J., Ramikie, T. S., Báldi, R., Hermanson, D. J., Kingsley, P. J., Marnett, L. J., Winder, D. G., Colbran, R. J., & Patel, S. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.11.001 · Cited by 155
García-Gutiérrez, M. S., & Manzanares, J. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379507 · Cited by 153
Self-citationHu, B., Doods, H., Treede, R.-D., & Ceci, A. (2009) · Pain · doi:10.1016/j.pain.2009.02.018 · Cited by 138
The Efficacy and Safety of Nabilone (A Synthetic Cannabinoid) in the Treatment of Anxiety
FABRE, L. F., & McLENDON, D. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02617.x · Cited by 138
Ganon-Elazar, E., & Akirav, I. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.204 · Cited by 120
Bosch-Bouju, C., Larrieu, T., Linders, L., Manzoni, O. J., & Layé, S. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.082 · Cited by 100
Zhang, Z., Wang, W., Zhong, P., Liu, S. J., Long, J. Z., Zhao, L., Gao, H., Cravatt, B. F., & Liu, Q. (2015) · Hippocampus · doi:10.1002/hipo.22344 · Cited by 89
Rossi, S., De Chiara, V., Musella, A., Sacchetti, L., Cantarella, C., Castelli, M., Cavasinni, F., Motta, C., Studer, V., Bernardi, G., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064196 · Cited by 82
Degroot, A., & Nomikos, G. G. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03556.x · Cited by 58
Aliczki, M., Zelena, D., Mikics, E., Varga, Z. K., Pinter, O., Bakos, N. V., Varga, J., & Haller, J. (2013) · Hormones and Behavior · doi:10.1016/j.yhbeh.2013.03.017 · Cited by 50
Gutiérrez‐Rodríguez, A., Puente, N., Elezgarai, I., Ruehle, S., Lutz, B., Reguero, L., Gerrikagoitia, I., Marsicano, G., & Grandes, P. (2017) · Journal of Comparative Neurology · doi:10.1002/cne.24066 · Cited by 46
Almeida-Santos, A. F., Gobira, P. H., Rosa, L. C., Guimaraes, F. S., Moreira, F. A., & Aguiar, D. C. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.05.027 · Cited by 41
Verty, A. N. A., Boon, W. M., Mallet, P. E., McGregor, I. S., & Oldfield, B. J. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06750.x · Cited by 39
Gonda, X., Petschner, P., Eszlari, N., Sutori, S., Gal, Z., Koncz, S., Anderson, I. M., Deakin, B., Juhasz, G., & Bagdy, G. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00138 · Cited by 37
Cited by
García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306
Self-citationGonda, X., Petschner, P., Eszlari, N., Sutori, S., Gal, Z., Koncz, S., Anderson, I. M., Deakin, B., Juhasz, G., & Bagdy, G. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00138 · Cited by 37
Glutamate receptor 4 as a fluid biomarker for the diagnosis of psychiatric disorders
Gómez de San José, N., Goossens, J., Al Shweiki, M. R., Halbgebauer, S., Oeckl, P., Steinacker, P., Danzer, K. M., Graf, H., Schönfeldt-Lecuona, C., Belbin, O., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.10.010 · Cited by 9
Metadata
- Authors
- Navarrete, F., García-Gutiérrez, M. S., Jurado-Barba, R., Rubio, G., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2020-04-27
- Volume
- 11
- Pages
- 315-315
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W3019308918
- Cited by
- 133
- References
- 69
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.